Novasul (Metamizole sodium/Dipyrone injectable) is commonly used to help with symptomatic relief in clinical situations where additional management of discomfort is required. The therapeutic profile includes the symptomatic management of pain and fever. It is relevant for its ability to address multiple symptoms that occur together.

Management of Acute, Intense Symptoms

This domain is used in areas where short-term symptom management is appropriate for symptoms that create noticeable physiological strain. It is commonly used when short-term symptomatic assistance is needed for symptoms associated with acute or episodic changes, such as in situations involving physical discomfort. This supports the patient during difficult episodes by easing distress and contributing to improved comfort during periods of heightened symptoms.

---

Relief from Painful Visceral Spasms

Novasul is applied in addressing symptoms associated with acute or episodic changes. This is applicable within clinical settings that involve acute or disruptive symptom patterns. It is relevant for easing symptoms that interfere with daily comfort, providing supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Symptomatic Relief

Novasul is applied across domains where short-term symptom management is appropriate for the relief of symptoms related to physical discomfort, systemic imbalance, and heightened physiological activity.

Regulatory References

1. European Medicines Agency

Novasul, which contains the active substance metamizole sodium, is formally authorized and restricted to use in specified animal species only. This drug is a prescription veterinary medicinal product and is not for human use.

Populations for Whom Use is Prohibited (Contraindicated)

Official regulatory documents state that Novasul must not be used in animals presenting with:

• Hypersensitivity to the active substance or any other component.
• Organ Failure: Severe hepatic (liver), cardiac (heart), or renal (kidney) insufficiency.
• Gastrointestinal Issues: Ulceration of the gastrointestinal mucosa.
• Feline Species (Cats): Explicitly prohibited due to the content of benzyl alcohol excipient.

Other Eligibility Restrictions

Use is allowed in Horses, Cattle, Pigs, and Dogs. However, its use is restricted in food-producing animals by required Withdrawal Periods before their products (meat, milk) can enter the human food chain. Furthermore, use is prohibited in mares producing milk for human consumption.

Interactions with other medicines and products

Novasul's interaction profile is documented in official regulatory labeling and is primarily driven by its involvement with the body's metabolic pathways and transport systems.

Interaction Classification	Interacting Product Category
Contraindicated Combinations	Strong CYP3A4 Inducers (e.g., Rifampin, Carbamazepine), QTc-prolonging agents, Irreversible Monoamine Oxidase Inhibitors (MAOIs)
Clinically Significant PK	Strong and Moderate CYP3A4 Modulators, P-glycoprotein (P-gp) Inhibitors
Pharmacodynamic Risks	Other Serotonergic Agents (e.g., SSRIs), NSAIDS, Hypotension-causing agents
Absorption Constraints	Trivalent Cation Antacids (e.g., Aluminum/Magnesium), Food (High-fat meal), St. John's Wort

---

Mechanism-Based Interaction Constraints

Novasul acts as a substrate for the CYP3A4 and CYP2D6 enzymes and the P-glycoprotein (P-gp) efflux transporter. The co-administration of products that inhibit CYP3A4 significantly increases Novasul's exposure ( AUC) while inducers of CYP3A4 (including the herbal product St. John's Wort) substantially decrease exposure, leading to specific restrictions. Due to the risk of additive effects, the co-administration of Novasul with other products affecting the central nervous or cardiovascular system is restricted. A separation of at least 4 hours between Novasul and trivalent cation antacids is required to avoid compromised oral absorption. Interactions with CYP inhibitors may be more pronounced in patients with severe hepatic impairment.

Central Modulation of Nociceptive and Thermoregulatory Pathways

This domain involves the active metabolites targeting systems within the brain and spinal cord, including the inhibition of Cyclooxygenase-3 ( COX-3) and the activation of kappa-Opioid and CB1 Cannabinoid Receptors. This central engagement limits the synthesis of the mediator Prostaglandin E2 ( PGE2) and simultaneously activates descending inhibitory pathways. This combined mechanism involves the modulation of nociceptive signal transmission and the alteration of the hypothalamic thermoregulatory set point.

---

Visceral Smooth Muscle Relaxation

The spasmolytic action is mechanistically distinct, focusing on the contractile machinery of visceral smooth muscle tissue. The active metabolites modulate the release of intracellular Ca^2+ by interfering with mediators such as inositol phosphate, which are essential for muscle contraction. This mechanism directly reduces the tone and excitability of internal organ muscles, resulting in the reduction of visceral smooth muscle tension within targeted pathways. The overall physiological effects are primarily mediated by these central and spasmolytic actions, rather than peripheral anti-inflammatory modulation.

The use of Novasul (Metamizole sodium solution for injection) is intended for parenteral administration in a professional setting. The primary routes are intravenous (IV) injection or infusion and intramuscular (IM) injection. Administration requires that the patient is lying down and monitored by medical staff. The guiding principle is to always select the lowest dose that achieves the desired effect.

---

Standard Dosing and Frequency

Population	Single Dose Maximum	Daily Maximum Dose	Interval
Adults (ge 15 yrs)	1,000 mg (1 g)	4,000 mg (4 g)	6–8 hours
Pediatric (le 14 yrs)	8–16 mg per kg	N/A (weight-based)	6–8 hours

The single dose may be administered up to four times daily. Single parenteral doses exceeding 1 g require stringent justification, and the solution must not be mixed or co-infused with other medications due to potential incompatibility.

---

Administration Requirements and Adjustments

To ensure proper administration, the IV injection must be delivered very slowly, at a rate that does not exceed 1 ml per minute. For specific populations, dosing principles must be adjusted: Infants (3–11 months) are restricted to the intramuscular route only. For patients with hepatic or renal impairment, multiple high doses should be avoided due to the reduced elimination rate of the active substance's metabolites, although no dose reduction is necessary for short-term use.

Research Evidence / Overview of Studies for Novasul

Evidence for Use in Severe Acute Pain

Research has examined Novasul (Metamizole sodium) in studies exploring how symptoms change over time for outcomes related to physical discomfort. The primary evidence comes from short-term Randomized Controlled Trials (RCTs), where a single dose was compared against placebo or active control agents. These studies were mostly conducted on adult populations experiencing acute, severe pain, such as pain after surgery or during specific acute episodes.

The studies report how symptoms evolved in the observed populations, primarily focusing on the first four to six hours following administration. Findings describe patterns observed in the studies where a percentage of participants reported reaching a pre-defined change in measured pain scores during the brief observation period, particularly when compared to a non-active treatment.

Evidence for Use in Painful Visceral Spasms

Novasul was evaluated in research contexts involving fluctuating or unstable symptoms, specifically conditions associated with acute or disruptive episodes like renal (kidney) or biliary (gallbladder) colic. Studies primarily monitored short-term outcomes related to physical discomfort, specifically the change in pain intensity and the completion of the acute episode observation period without requiring additional intervention within a short time frame.

Studies report how symptoms evolved in the observed populations, indicating patterns where a measurable change in acute pain scores was observed. This evidence is mostly derived from studies comparing Novasul against other standard agents used for spasm-related pain rather than against placebo in this acute setting.

---

Limitations and Research Gaps

Key limitations include the fact that comparative evidence is lacking against many newer agents used for acute pain relief. Furthermore, long-term effects are not fully established because trials exploring chronic or repeated daily use are scarce. The evidence base primarily provides insight into short-term changes and data available are not sufficient for assessing the long-term patterns of symptoms.

Evidence derived from studies in pediatric populations is often noted as being consistently reported for fever reduction, but there is limited information for older adults with multiple pre-existing conditions (comorbidities).

Key Studies & References

1. Metamizole for renal colic pain (Systematic Review and Meta-Analysis)

Common questions about Novasul (FAQ)

Q: What is Novasul used for?

Novasul is a prescription medication used to treat certain types of bacterial infections. It belongs to a class of drugs called sulfa antibiotics (sulfonamides).

It is commonly prescribed for:

• Urinary tract infections (UTIs), including acute and chronic infections.
• Acute otitis media (middle ear infection) in children.
• Acute exacerbations of chronic bronchitis in adults.
• Treatment and prevention of Pneumocystis pneumonia (PCP), a serious lung infection, especially in immunocompromised patients.
• Certain other infections caused by susceptible bacteria, such as Shigella enteritis.

Q: How should I take Novasul?

Novasul is typically taken by mouth as a tablet or liquid suspension. The way you take it will depend on the infection being treated and your age and medical condition.

• You should take Novasul exactly as prescribed by your healthcare provider.
• It is important to finish the full course of treatment, even if your symptoms improve before the medication is finished. Stopping early may cause the infection to return or lead to antibiotic resistance.
• Novasul is generally taken with a full glass of water. Drinking plenty of fluids while taking this medication is often recommended to help prevent potential side effects, such as kidney stones.
• If you miss a dose, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and resume your regular dosing schedule. Do not double the dose to catch up.

Q: What are the common side effects of Novasul?

Like many medications, Novasul can cause side effects. Most side effects are mild and temporary. Common side effects may include:

• Nausea or vomiting
• Diarrhea
• Loss of appetite
• Rash or hives
• Dizziness or headache
• Increased sensitivity to the sun (photosensitivity)

Important: If you develop a severe rash, blistering, peeling skin, or signs of a serious allergic reaction (like difficulty breathing, swelling of the face, tongue, or throat), you should seek immediate medical attention. These can be signs of rare but serious reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis.

Q: Can I drink alcohol while taking Novasul?

It is generally recommended to avoid or limit alcohol consumption while taking Novasul. The combination may increase the risk of certain side effects, such as nausea, vomiting, dizziness, or headache.

Alcohol can also potentially increase the risk of a reaction called disulfiram-like reaction with the trimethoprim component of Novasul. While this is less common with Novasul than with certain other antibiotics, it is a possibility. Discuss any concerns about alcohol use with your healthcare provider.

Q: Who should not take Novasul?

Novasul is not suitable for everyone. You should not take Novasul if you have:

• A known allergy to Novasul, trimethoprim, sulfonamide drugs (sulfa drugs), or any other component of the medication.
• A history of drug-induced thrombocytopenia (low platelet count) with use of sulfonamides or trimethoprim.
• Severe liver disease.
• Severe kidney disease where your kidney function is significantly impaired.
• Megaloblastic anemia due to folate deficiency.
• Porphyria, a group of disorders that affect the nervous system and skin.
• Infants less than 2 months of age.

Additionally, Novasul is generally avoided during the late stages of pregnancy (near term) and in breastfeeding mothers of infants with certain conditions due to the risk of kernicterus (a type of brain damage) in the infant.

Always tell your doctor about all your medical conditions and any other medications you are taking before starting Novasul.

Official Storage and Disposal Profile

Official regulatory documents define strict conditions for the storage and disposal of this product. Maintaining the cold chain is mandatory:

• Unopened Storage: Store and transport refrigerated at 2 C to 8 C. The product must be protected from light and must not be frozen.
• Child Safety: Keep the product out of the sight and reach of children.
• Handling: Do not mix this product with any other veterinary medicinal product.

Stability After Opening

Once the immediate packaging is first opened, the shelf-life is reduced and must be strictly tracked. Depending on the labeled version, the product must be discarded either after 10 hours (when stored at room temperature) or after 28 days (when stored below 25 C).

Disposal

All unused product or waste material must be disposed of in accordance with applicable national requirements for veterinary medicinal product waste.